Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease
ABSTRACT Background Impulsivity and dopamine dysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD). Methods We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PD patients with motor complications and severe impulsivity and...
Saved in:
Published in: | Movement disorders Vol. 28; no. 14; pp. 2007 - 2010 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Blackwell Publishing Ltd
01-12-2013
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
Background
Impulsivity and dopamine dysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD).
Methods
We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PD patients with motor complications and severe impulsivity and dopamine dysregulation syndrome (DDS), which had not be controlled before by adjusting oral medications. The infusion was delivered during 15 hours (daily dose 1007.2 ± 302.5 mg) and stopped at night time. Patients were reassessed after 25 ± 9 weeks of treatment with a stable dose of jejunal l‐dopa.
Results
Off periods and dyskinesias decreased by 27% and 20,7% respectively, compared to baseline. DDS and all types of impulse control disorders (ICDs) improved in all patients, with nearly complete symptom resolution. Punding improved in all 5 patients but disappeared completely in only 1.
Conclusions
Our experience suggests that l‐dopa infusion has a positive effect on both motor complications and behavioral disorders. This treatment approach deserves further controlled studies. © 2013 International Parkinson and Movement Disorder Society |
---|---|
Bibliography: | ark:/67375/WNG-8JJDV6D9-S ArticleID:MDS25636 istex:A84AEA35A0CD1C5E00ADF722F205130AB91C0B36 Full financial disclosures and author roles may be found in the online version of this article. Nothing to report. Relevant conflicts of interest/financial disclosures Funding agencies This study was partially supported by a grant from Ministerio de Ciencia e Innovación, Instituto Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED INTCBN 09/203), Madrid, Spain. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.25636 |